title: A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
abstract: BACKGROUND
  The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). Adiponectin, an adipocyte-derived circulating protein, has anti-atherosclerotic and anti-diabetic properties and is effectively elevated in bloodstream by thiazolidinediones, an insulin sensitizer. However, the effect of sitagliptin treatment on serum adiponectin level in T2DM has not fully elucidated in Japanese T2DM patients. The aim of the present study was to examine the effect of sitagliptin treatment on serum adiponectin levels in T2DM subjects.
  
  
  METHODS
  Twenty-six consecutive Japanese T2DM outpatients were recruited between April 2011 and March 2013, and randomized into the control (conventional treatment, n = 10) group and sitagliptin treatment group (n = 16). Serum adiponectin was measured by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Indices of glycemic control, such as hemoglobin A1c, glycated albumin, and 1.5-anhydro-D-glucitol, were significantly improved after the three-month treatment in both the control and sitagliptin groups. Serum adiponectin level was significantly increased in sitagliptin group from 6.7 ± 0.8 to 7.4 ± 1.0 μg/mL without change of body mass index (p = 0.034), while serum adiponectin level was not altered in the control group (p = 0.601).
  
  
  CONCLUSIONS
  In Japanese T2DM patients, serum adiponectin level was elevated by three-month treatment with sitagliptin without change of body weight.
  
  
  BACKGROUND
  UMIN000004721.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Hibuse
authors.affiliation: Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan. norikazu_maeda@endmet.med.osaka-u.ac.jp.
authors.forename: Norikazu
authors.initials: N
authors.lastname: Maeda
authors.forename: Ken
authors.initials: K
authors.lastname: Kishida
authors.forename: Takekazu
authors.initials: T
authors.lastname: Kimura
authors.forename: Tomoko
authors.initials: T
authors.lastname: Minami
authors.forename: Eriko
authors.initials: E
authors.lastname: Takeshita
authors.forename: Ayumu
authors.initials: A
authors.lastname: Hirata
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Susumu
authors.initials: S
authors.lastname: Kashine
authors.forename: Akemi
authors.initials: A
authors.lastname: Oka
authors.forename: Masumi
authors.initials: M
authors.lastname: Hayashi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nishizawa
authors.forename: Tohru
authors.initials: T
authors.lastname: Funahashi
authors.forename: Iichiro
authors.initials: I
authors.lastname: Shimomura
mesh_terms: D052242:Adiponectin / Q000096:biosynthesis / Q000097:blood*; D000368:Aged; D044466:Asian People / Q000208:ethnology; D015415:Biomarkers / Q000097:blood; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000208:ethnology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate